Clinical trials: Pancreas Cancer
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Gastric Cancer, Colon Cancer
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in…
- Conditions
- Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer
- Trial name
- NCT06006390
- Testing
- CEA-targeted CAR-T cells
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Anal Carcinoma, Bladder Carcinoma
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and…
- Conditions
- Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma
- Trial name
- NCT07118176
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Pancreatic Cancer
Detection of High Expression Levels of EMT-Transcription Factor mRNAs in Patients With Pancreatic Cancer and Their Diagnostic Potential
The present study is aimed at detecting and measuring mRNA levels of genes involved in epithelial to mesenchymal transition (EMT) in biological samples, i.e.
- Trial name
- NCT04323917
- Testing
- Liquid biopsy
- Where
- Italy
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
Cancer, Pancreas
Effect of Oncothermia on Improvement of Quality of Life in Unresectable Pancreatic Cancer Patients
Patients with pancreatic cancer often suffer from pain. Because of such a pain, their quality of life have seriously deteriorated.
- Trial name
- NCT02150135
- Testing
- Oncothermia
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Seoul National University Hospital
Carcinoma, Pancreatic Ductal
Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study.
Rationale: Pancreatic adenocarcinoma is a malignancy with a poor prognosis. Resection is the only curative option and still 5-year survival rate is less than 10 percent.
- Trial name
- OPT-1 (NCT03500068)
- Testing
- biopsies & blood analyses
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pancreatic Cancer
Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer
The aim of this study is to determine the usefulness of circulating tumor DNA as a prognostic factor in patients with pancreatic cancer.
- Trial name
- NCT03214991
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Ji Kon Ryu
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer, Pancreatic Cancer
Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos
The study consists in a co-clinical trial by using zebrafish embryos. Specifically, an observational prospective clinical trial on patients operated of epato-biliar-pancreatic cancers and gastro-intestinal cancers undergoing a…
- Conditions
- Liver Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- xenoZ (NCT03668418)
- Testing
- Fluorouracil, Lederfolin, Oxaliplatin
- Where
- Italy
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Pisa
Malnutrition, Pancreatic Cancer
Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Pancreatic enzymes may help kill cancer cells.
- Trial name
- NCT00003851
- Testing
- proteolytic enzymes, gemcitabine hydrochloride, Gonzalez regimen
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Columbia University
Metastatic Pancreatic Ductal Adenocarcinoma
A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.
- Trial name
- CAPAFOUR (NCT04990037)
- Testing
- CAN04, FOLFIRINOX
- Where
- 9 sites in France, Spain
- Volunteers
- 25 people
- Sponsor
- Cantargia AB
Pancreatic Cancer, Perioperative/Postoperative Complications
Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection
RATIONALE: Drugs such as vapreotide may prevent complications following pancreatic resection. It is not yet known if vapreotide is more effective than no further therapy in preventing side effects of pancreatic resection.
- Trial name
- NCT00014651
- Testing
- vapreotide, conventional surgery
- Where
- 18 sites in United States
- Sponsor
- Mayo Clinic
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
Pancreatic Cancer, Surgery
Quality of Life in Elderly Patients After Pancreatic Cancer Surgery
Pancreatic cancer mainly affects the elderly, with over 85% of patients diagnosed after the age of 60 and over half after the age of 70.
- Conditions
- Pancreatic Cancer, Surgery, Elderly
- Trial name
- ADL_DPC_PA (NCT06079229)
- Testing
- Phone call
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Hospices Civils de Lyon
Pancreatic Adenocarcinoma, Predictive Cancer Model
Prospective Validation of an EHR-based Pancreatic Cancer Risk Model
The goal of this prospective observational cohort study is to validate a previously developed pancreatic cancer risk prediction algorith (the PRISM model) using electronic health records from the general population.
- Trial name
- NCT05973331
- Testing
- Pancreatic Cancer Risk Model (PRISM)
- Where
- United States
- Volunteers
- 6,134,060 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Pancreatic Cancer
Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma
The research purpose of this project is to create a registry, and blood and tissue bank for individuals at high-risk for pancreatic cancer.
- Trial name
- NCT01219829
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Columbia University
Pancreas Cancer, Exosomes
ExoLuminate Study for Early Detection of Pancreatic Cancer
ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC).
- Conditions
- Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms
- Trial name
- NCT05625529
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Biological Dynamics
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery…
- Conditions
- Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- LOTUS (NCT06073431)
- Testing
- Biospecimen Collection, Computed Tomography, Electronic Health Record Review
- Where
- 225 sites in United States
- Volunteers
- 800 people
- Sponsor
- University of Rochester
Pancreatic Cancer
A Study of Ruxolitinib in Pancreatic Cancer Patients
This was to determine the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of metastatic pancreatic cancer.
- Trial name
- NCT02119663
- Testing
- Ruxolitinib, Capecitabine
- Where
- 95 sites in United States, Austria and 12 more
- Volunteers
- 86 people
- Sponsor
- Incyte Corporation
Pancreatic Cancer, Neoplasm Metastasis
Tarceva and Capecitabine for Pancreatic Cancer
This phase II trial is designed to investigate the effectiveness of Tarceva (OSI-774) combined with capecitabine in treating patients with metastatic pancreatic cancer.
- Trial name
- NCT00125021
- Testing
- Capecitabine, OSI-774
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute